PMID- 19573120
OWN - NLM
STAT- MEDLINE
DCOM- 20100222
LR  - 20191210
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 26
IP  - 7
DP  - 2009 Jul
TI  - The effect of anti-inflammatory (aspirin and/or statin) therapy on body weight in 
      Type 2 diabetic individuals: EAT, a retrospective study.
PG  - 708-13
LID - 10.1111/j.1464-5491.2009.02747.x [doi]
AB  - AIMS: Obesity is associated with inflammation. Anti-inflammatory interventions 
      such as aspirin and statins (anti-IFRx) might be a novel approach to the 
      treatment of obesity and Type 2 diabetes mellitus (T2DM). The present study was 
      designed to determine whether exposure to anti-IFRx is associated with weight 
      loss in T2DM patients. METHODS: Exposure to anti-IFRx was compared between T2DM 
      patients with a history of weight loss (n = 100) and those with no weight loss or 
      with weight gain (n = 102) during a 1-year follow-up period. Logistic regression 
      was used to develop odds ratios for weight loss status. RESULTS: Subjects who 
      lost weight were more frequently exposed to anti-IFRx (85.0 vs. 71.5%, P = 0.018) 
      than subjects who maintained or gained weight during follow-up. The 158 subjects 
      exposed to anti-IFRx were older (64.2 +/- 9.4 vs. 60.6 +/- 11.2 years, P = 0.04), 
      had longer duration T2DM (14.5 +/- 9.5 vs. 9.0 +/- 9.4 years, P = 0.001), had 
      greater prevalence of dyslipidaemia (72 vs. 19%, P < 0.0001) hypertension (57.3 
      vs. 38.1%, P = 0.03) and cardiovascular disease (37.7 vs. 9.5%, P < 0.0001) than 
      subjects not exposed to anti-IFRx. In a logistic regression model for weight 
      change status, anti-IFRx exposure was significantly associated with weight status 
      (odds ratio = 2.3, 95% confidence interval 1.1-4.8, P = 0.02, an association that 
      persisted), even after controlling for age, sex, baseline body mass index, years 
      since diagnosis, OHA therapy and co-morbidities. CONCLUSIONS: Exposure to 
      anti-IFRx more than doubled the odds of weight loss in T2DM patients. Results of 
      this study justify a randomized clinical trial to determine definitively the role 
      of anti-IFRx in weight loss in subjects with T2DM.
FAU - Boaz, M
AU  - Boaz M
AD  - Epidemiology and Research Unit, Wolfson Medical Center, Holon, Israel. 
      mboaz8@yahoo.com
FAU - Lisy, L
AU  - Lisy L
FAU - Zandman-Goddard, G
AU  - Zandman-Goddard G
FAU - Wainstein, J
AU  - Wainstein J
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use
MH  - Aspirin/*pharmacology/therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology/therapeutic use
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Obesity/metabolism
MH  - Retrospective Studies
MH  - Weight Loss/*drug effects
MH  - Young Adult
EDAT- 2009/07/04 09:00
MHDA- 2010/02/23 06:00
CRDT- 2009/07/04 09:00
PHST- 2009/07/04 09:00 [entrez]
PHST- 2009/07/04 09:00 [pubmed]
PHST- 2010/02/23 06:00 [medline]
AID - DME2747 [pii]
AID - 10.1111/j.1464-5491.2009.02747.x [doi]
PST - ppublish
SO  - Diabet Med. 2009 Jul;26(7):708-13. doi: 10.1111/j.1464-5491.2009.02747.x.